Oxazine drug-seed induces paraptosis and apoptosis through reactive oxygen species/JNK pathway in human breast cancer cells

Na Young Kim, Dukanya Dukanya, Gautam Sethi, Swamy Savvemala Girimanchanaika, Ji-Rui Yang, Omantheswara Nagaraja, Ananda Swamynayaka, Divakar Vishwanath, Keerthikumara Venkantesha, Shreeja Basappa,

Translational Oncology · 2024 · 16 citations · 60 references

DOIFull text

Open access

Concepts

Abstract

• To overcome drug-resistant breast cancer, it is essential to develop compounds that induce apoptosis and paraptosis. • BSO-07 triggered G1 phase arrest, cleaved PARP, inhibited bcl-2, bcl-xL and survivin, and upregulated ATF4, CHOP, and p-JNK expression. • BSO-07 induced both apoptosis and paraptosis via the reactive oxygen species and JNK pathway in human BC cells. Small molecule-driven JNK activation has been found to induce apoptosis and paraptosis in cancer cells. Herein pharmacological effects of synthetic oxazine (4 aS , 7 aS )-3-((4-(4‑chloro-2-fluorophenyl)piperazin-1-yl)methyl)-4-phenyl-4, 4 a , 5, 6, 7, 7 a -hexahydrocyclopenta[ e ] [1,2]oxazine (FPPO; BSO-07) on JNK-driven apoptosis and paraptosis has been demonstrated in human breast cancer (BC) MDA-MB231 and MCF-7 cells respectively. BSO-07 imparted significant cytotoxicity in BC cells, induced activation of JNK, and increased intracellular reactive oxygen species (ROS) levels. It also enhanced the expression of apoptosis-associated proteins like PARP, Bax, and phosphorylated p53, while decreasing the levels of Bcl-2, Bcl-xL, and Survivin. Furthermore, the drug altered the expression of proteins linked to paraptosis, such as ATF4 and CHOP. Treatment with N-acetyl-cysteine (antioxidant) or SP600125 (JNK inhibitor) partly reversed the effects of BSO-07 on apoptosis and paraptosis. Advanced in silico bioinformatics, cheminformatics, density Fourier transform and molecular electrostatic potential analysis further demonstrated that BSO-07 induced apoptosis and paraptosis via the ROS/JNK pathway in human BC cells.

References

60